Trinity Biotech plc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 14.68 million compared to USD 15.7 million a year ago. Net loss was USD 6.72 million compared to USD 8.95 million a year ago. Basic loss per share was USD 0.88 compared to USD 1.18 a year ago. Diluted loss per share was USD 0.88 compared to USD 1.18 a year ago.
For the nine months, sales was USD 43.4 million compared to USD 46.8 million a year ago. Net loss was USD 18.52 million compared to USD 30.93 million a year ago. Basic loss per share was USD 2.42 compared to USD 4.8 a year ago. Diluted loss per share was USD 2.42 compared to USD 4.8 a year ago.